Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer

Johnson & Johnson (NYSE: JNJ) announces it has entered into a definitive agreement to acquire Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billion net of estimated cash acquired. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety of its candidate therapeutics in multiple cancer indications.

Read the full article: Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer //

Source: https://www.businesswire.com/news/home/20240108905189/en/Johnson-Johnson-to-Acquire-Ambrx-Advancing-Next-Generation-Antibody-Drug-Conjugates-to-Transform-the-Treatment-of-Cancer

Leave a Comment

Your email address will not be published.

Scroll to Top